InvestorsHub Logo
Followers 2
Posts 436
Boards Moderated 0
Alias Born 01/14/2014

Re: georgejjl post# 282

Tuesday, 12/15/2015 10:05:04 AM

Tuesday, December 15, 2015 10:05:04 AM

Post# of 807
But the biggest Intercept beneficiary overall is Italian biopharma investment company Genextra, which owns a 30% stake in the company now worth about $2.6 billion — a $2.2 billion increase in the past week. Genextra, which is closely held, hasn’t disclosed its ownership structure, but it’s likely that Francesco Micheli, co-founder and chairman of Genextra and a former billionaire, and Dr. Lorenzo Tallarigo, Genextra’s CEO, have made a fortune off Intercept Pharmaceutical’s remarkable stock movement.